|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 469.60 DKK | -3.43% |
|
-10.62% | -34.37% |
| 01:27am | Deutsche Bank raises its target price for Zealand Pharma to DKK 450 (430), reiterates hold | FW |
| Dec. 15 | Zealand Pharma A/S - Analyst/Investor Day |
| Capitalization | 33.01B 5.2B 4.42B 4.13B 3.87B 7.15B 473B 7.84B 48.27B 18.62B 222B 19.51B 19.1B 805B | P/E ratio 2025 * |
5.56x | P/E ratio 2026 * | 28.4x |
|---|---|---|---|---|---|
| Enterprise value | 21.72B 3.42B 2.91B 2.72B 2.55B 4.7B 311B 5.16B 31.76B 12.25B 146B 12.83B 12.57B 530B | EV / Sales 2025 * |
2.44x | EV / Sales 2026 * | 4.31x |
| Free-Float |
99.18% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | -3.95% | ||
| 1 week | -10.62% | ||
| Current month | -9.06% | ||
| 1 month | -8.57% | ||
| 3 months | +9.54% | ||
| 6 months | +4.03% | ||
| Current year | -34.37% |
| 1 week | 466 |  | 525 |
| 1 month | 466 | | 556 |
| Current year | 306.1 | | 808 |
| 1 year | 306.1 | | 809 |
| 3 years | 189.3 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 2022-03-29 | |
| Director of Finance/CFO | - | 2022-10-31 | |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 63 | 2022-06-01 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 2018-04-18 |
| Director/Board Member | 66 | 2019-04-03 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0% | 51 M€ | +18.34% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.43% | -10.62% | -39.83% | +133.63% | 5.38B | |
| +0.41% | -7.27% | +25.10% | +95.48% | 52.08B | |
| +1.90% | +3.35% | +173.43% | +950.63% | 42B | |
| -2.29% | -2.65% | +57.73% | +13.89% | 38.48B | |
| -1.68% | -3.78% | -19.25% | -47.37% | 22.56B | |
| -1.32% | -3.38% | +38.10% | -36.86% | 19.52B | |
| -1.17% | -2.67% | +80.11% | -34.10% | 17.21B | |
| +0.60% | -6.03% | +83.66% | +187.22% | 13.75B | |
| -0.86% | +1.23% | -7.76% | +377.29% | 13.4B | |
| +0.45% | -9.29% | +115.57% | - | 12.06B | |
| Average | -0.79% | -4.90% | +50.69% | +182.20% | 23.64B | |
| Weighted average by Cap. | -0.38% | -4.34% | +62.29% | +229.11% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.91B 1.4B 1.19B 1.12B 1.05B 1.93B 128B 2.11B 13.03B 5.03B 59.94B 5.26B 5.15B 217B | 4.9B 771M 655M 613M 575M 1.06B 70.13B 1.16B 7.16B 2.76B 32.95B 2.89B 2.83B 119B |
| Net income | 5.95B 938M 797M 745M 699M 1.29B 85.28B 1.41B 8.71B 3.36B 40.06B 3.52B 3.45B 145B | 1.16B 183M 155M 145M 136M 252M 16.64B 276M 1.7B 656M 7.82B 687M 672M 28.34B |
| Net Debt | -11.29B -1.78B -1.51B -1.41B -1.33B -2.45B -162B -2.68B -16.51B -6.37B -75.99B -6.67B -6.53B -275B | -11.9B -1.88B -1.59B -1.49B -1.4B -2.58B -170B -2.82B -17.4B -6.71B -80.08B -7.03B -6.89B -290B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 469.60 kr | -3.43% | 351,495 |
| 25-12-15 | 486.30 kr | -1.32% | 379,043 |
| 25-12-12 | 492.80 kr | -4.16% | 478,306 |
| 25-12-11 | 514.20 kr | +0.43% | 366,871 |
| 25-12-10 | 512.00 kr | +1.19% | 296,513 |
Delayed Quote Nasdaq Copenhagen, December 16, 2025 at 11:20 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
